米国における異業種企業100社のバイオ技術開発と事業化動向

Abstract

Research Objectives

This Fuji-Keizai USA report explores research and development activities, business operations, investments and overall policies on biotechnology from the non-pharmaceutical, non-biotech company perspective. The organizations included in this report were selected because their core business is outside pure-play biotechnology and pharmaceutical drug development. The purpose is to understand to what extent, and why, industries such as IT, chemical companies, electronics giants, energy companies, among others, have an interest in biotechnology.

Target Companies

We start with a big picture of 100 non-pharma, non-biotech organizations. The organizations are predominantly U.S. Fortune 500 and European Fortune Global 500 businesses, as well as top U.S. hospitals and educational institutions. Next, we look at a piece of that organization - the divisional picture - and describe the business unit or other internal group, often within R&D, that is advancing biotechnology, either through commercialization of a product, internal research and/or a strategy of partnerships or acquisition. Our sources were publicly available data and phone interviews. Because the organizations come from different industrial sectors, their uses for biotechnology range from medicine, to consumer products such as clothing and food, to biofuel production. One of more biotechnology-related projects at each of the companies is described.

Biotechnology Defined

Biotechnology is synonymous with genomics (the study of genes) and proteomics (the study of proteins), where molecular biology and information technology are the tools used by scientists to develop advanced drugs. Because our scope is beyond pharmaceutical biotech alone, we have broadened the definition of biotechnology for this report to mean any technology where biological substances (e.g., human cells, tissue, plants, microorganisms, enzymes, etc.) are converted into a marketable product, system or process for medical or/and industrial application.

Overview of R&D Trends

• 1. Development of drugs or therapies to improve human health is still a primary focus of biotechnology research being done outside of the pharmaceuticals industry.
• 2. Commercialization of biotechnologies as applied to industrial processes is the next wave.
• 3. Fortune 500 companies have or are refashioning their role in the biotech universe in the face of marketplace realities.
• 4. Major consumer-oriented companies are showing a willingness to get involved in a new generation of biotech food research.

Table of Contents

• 1. Overview if R&D Trends and Directions
• 2. R&D Trends by Companies
  • 2.1 Percent (%) Share by Company Type (Breakdown)
  • 2.2 Percent (%) Share by Target R&D Segment
  • 2.3 Share by Target R&D Segment, by Company Type
  • 2.4 Other Analysis Based on Individual Company' s Activity
  • 2.5 Market Size and R&D
• 3. Case Studies of 100 Companies
  • Common Research Item
    • 1) Company Name and Contact Information
    • 2) Biotechnology Division Name and Contact Information
    • 3) Division' s Function within Organization (Why does the company need this kind of Division? Why does it invest in this area of biotech development?)
    • 4) Division Information (# of staff, budget, etc)
    • 5) R&D description (technology, application, etc)
    • 6) Technology or/and Application Competitive Advantages
    • 7) Strategic Alliances
    • 8) Business Segment: Market size Forecast